Advances in the management of metastatic breast cancer: Options beyond first-line chemotherapy

Current Oncology

Volumn 19, Issue 2, 2012, Pages 91-105

  Ayoub, J P M ^a   Verma, Shailendra ^b   Verma, Su ^c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Breast cancer; Chemotherapy; Eribulin; Ixabepilone; MBC; Metastatic; Nab paclitaxel; Pretreated

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERIBULIN; FLUOROURACIL; GEMCITABINE; IXABEPILONE; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; RAMUCIRUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CONSTIPATION; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENT CANCER; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 84859463274     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1024     Document Type: Article

References (85)

1. Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M on behalf of the esmo Guidelines Working Group. Locally recurrent or metastatic breast cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v15-19.
2. Morris PG, McArthur HL, Hudis CA. Therapeutic options for metastatic breast cancer. Expert Opin Pharmacother 2009;10:967-81.
3. World Health Organization (who). Global cancer rates could increase by 50% to 15 million by 2020 [press release]. Geneva, Switzerland: who; 2003. [Available online at: http://www.who.int/mediacentre/news/releases/2003/pr27/en/; cited October 15, 2011]
4. El Saghir NS, Tfayli A, Hatoum HA, Nachef Z, Dinh P, Awada A. Treatment of metastatic breast cancer: state-ofthe- art, subtypes and perspectives. Crit Rev Oncol Hematol 2011;80:433-49.
5. Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010;102:456-63.
6. Sørlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004;40:2667-75.
7. Dawood S. Triple negative breast cancer: epidemiology and management options. Drugs 2010;70:2247-58.
8. Orlando L, Colleoni M, Fedele P, et al. Management of advanced breast cancer. Ann Oncol 2007;18(suppl 6):vi74-6.
9. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
10. Verma S, McLeod D, Batist G, Robidoux A, Martins IR, Mackey JR. In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 2011;16:25-35.
11. Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 2009;84:533-45.
12. Gradishar WJ. The place for eribulin in the treatment of metastatic breast cancer. Curr Oncol Rep 2011;13:11-16.
13. Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 2007;21:257-72.
14. Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2011;9:136-222.
15. Dean-Colomb W, Esteva FJ. Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol 2008;35(suppl 2):S31-8.
16. Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009;20:1771-85.
17. Dufresne A, Pivot X, Tournigand C, et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat 2008;107:275-9.
18. Bristol-Myers Squibb. Ixempra (Ixabepilone) Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company; 2010.
19. Martín M, Ruiz A, Muñoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase iii Spanish Breast Cancer Research Group (geicam) trial. Lancet Oncol 2007;8:219-25.
20. Possinger K, Kaufmann M, Coleman R, et al. Phase ii study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 1999;10:155-62.
21. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase ii trial. Oncology 2002;62:2-8.
22. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3950-7.
23. Martín M, Sánchez-Rovira P, Muñoz M, et al. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in her2-positive metastatic breast cancer patients: efficacy and cardiac safety from the geicam/2004-05 study. Ann Oncol 2011;22:2591-6.
24. Fiegl M, Mlineritsch B, Hubalek M, Bartsch R, Pluschnig U, Steger GG. Single-agent pegylated liposomal doxorubicin (pld) in the treatment of metastatic breast cancer: results of an Austrian observational trial. BMC Cancer 2011;11:373.
25. Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 2004;30:53-81.
26. Lorusso V, Manzione L, Silvestris N. Role of liposomal anthracyclines in breast cancer. Ann Oncol 2007;18(suppl 6):vi70-3.
27. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (embrace): a phase 3 open-label randomised study. Lancet 2011;377:914-23.
28. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95.
29. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase ii study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27:2954-61.
30. Cortes J, Vahdat L, Blum JL, et al. Phase ii study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28:3922-8.
31. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-17.
32. Denduluri N, Swain SM. Ixabepilone for the treatment of solid tumors: a review of clinical data. Expert Opin Investig Drugs 2008;17:423-35.
33. Gerth K, Bedorf N, Höfle G, Irschik H, Reichenbach H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (myxobacteria). Production, psycho-chemical and biological properties. J Antibiot (Tokyo) 1996;49:560-3.
34. Ribeiro JT, Macedo LT, Curigliano G, et al. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? Ann Oncol 2011;:[Epub ahead of print].
35. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with Taxol-like mechanism of action. Cancer Res 1995;55:2325-33.
36. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science 2004;305:866-9.
37. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase ii study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14.
38. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37.
39. Lee FY, Camuso A, Castenada C, et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts [abstract 12017]. J Clin Oncol 2006;24:. [Available online at: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=34846; cited February 9, 2012]
40. Thomas E, Tabernero J, Fornier M, et al. Phase ii clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-406.
41. Low JA, Wedam SB, Lee JJ, et al. Phase ii clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-34.
42. Roché H, Yelle L, Cognetti F, et al. Phase ii clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-20.
43. Bunnell C, Vahdat L, Schwartzberg L, et al. Phase i/ii study of ixabepilone plus capecitabine in anthracycline-pretreated/ resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 2008;8:234-41.
44. Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase iii trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010;28:3256-63.
45. Hortobagyi GN, Gomez HL, Li RK, et al. Analysis of overall survival from a phase iii study of ixabepilone plus capecitabine versus capecitabine in patients with mbc resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2010;122:409-18.
46. Rivera E, Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res 2010;12(suppl 2):S2.
47. Goodin S. Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer. Am J Health Syst Pharm 2008;65:2017-26.
48. Pivot X, Villanueva C, Chaigneau L, et al. Ixabepilone, a novel epothilone analog in the treatment of breast cancer. Expert Opin Investig Drugs 2008;17:593-9.
49. Ibrahim NK. Ixabepilone development across the breast cancer continuum: a paradigm shift. Cancer Manag Res 2010;2:169-79.
50. Moulder S, Li H, Wang M, et al. A phase ii trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with her2- positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat 2010;119:663-71.
51. Gianni L, Dalenc F, De Benedictis E, et al. Clinical and pharmacokinetic study of ixabepilone (ixa) plus epirubicin (epi) as therapy for women with advanced breast cancer (bc). Cancer Res 2009;69(suppl 3):2097.
52. Lee F, Jure-Kunkel MN, Salvati ME. Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. Ther Adv Med Oncol 2011;3:11-25.
53. Yamamoto Y, Kawano I, Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety and approval. Onco Targets Ther 2011;4:123-36.
54. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991;83:288-91.
55. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;277:665-7.
56. Nyman DW, Campbell KJ, Hersh E, et al. Phase i and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23:7785-93.
57. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase iii trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
58. Ibrahim NK, Samuels B, Page R, et al. Multicenter phase ii trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23:6019-26.
59. Blum JL, Savin MA, Edelman G, et al. Phase ii study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7:850-6.
60. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-19.
61. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM. On behalf of North Central Cancer Treatment Group. Phase ii trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009;20:449-53.
62. Mirtsching B, Cosgriff T, Harker G, Keaton M, Chidiac T, Min M. Single agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network Study, #I-04-012) [abstract 1118]. J Clin Oncol 2008;26:. [Available online at: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35599; cited February 9, 2012]
63. Danso MA, Blum JL, Robert NJ, et al. Phase ii trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer [abstract 1075]. J Clin Oncol 2008;26:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33192; cited February 9, 2012]
64. Chirgwin J, Chua SL. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review. Breast 2011;20:394-406.
65. Somer BG, Schwartzberg LS, Arena F, et al. Phase ii trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel: abx) + capecitabine (xel) in first line treatment of metastatic breast cancer (mbc) [abstract 1053]. J Clin Oncol 2007;25:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=36215; cited February 9, 2012]
66. Vishnu P, Roy V. Safety and efficacy of nab-paclitaxel in the treatment of patients with breast cancer. Breast Cancer (Auckl) 2011;5:53-65.
67. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase ii study of capecitabine in paclitaxel-refractory metastatic breast carcinoma patients. Cancer 2001;92:1759-68.
68. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase ii study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93.
69. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase ii study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40:536-42.
70. O'Shaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase ii trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous cmf (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/ metastatic breast cancer. Ann Oncol 2001;12:1247-54.
71. Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase ii trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86:1367-72.
72. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-61.
73. Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase ii study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-33.
74. Stockler MR, Harvey VJ, Francis PA, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2011;29:4498-504.
75. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase iii trial results. J Clin Oncol 2002;20:2812-23.
76. Zielinski C, Gralow J, Martin M. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? Ann Oncol 2010;21:2145-52.
77. Pierre Fabre Pharma Canada. Navelbine (Vinorelbine Tartrate) Injection [product monograph]. St-Bruno de Montarville, QC: Pierre Fabre Pharma Canada; 2005.
78. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001;92:2267-72
79. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994;5:423-6.
80. Gasparini G, Caffo O, Barni S, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase ii study. J Clin Oncol 1994;12:2094-101.
81. Valero V, Hortobagyi GN. Are anthracycline-taxane regimens the new standard of care in the treatment of breast cancer? J Clin Oncol 2003;21:959-62.
82. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in the treatment of metastatic breast cancer. Oncologist 2004;9:617-32.
83. Sledge GW, Neuberg D, Bernardo P, et al. Phase iii trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 2003;21:588-92.
84. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase iii trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all her-2 overexpressors and random assignment to trastuzumab or not in her-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-9.
85. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008;26:1987-92